FTSE MIB
33.899,90 +270,69 (+0,80%) Dow Jones
38.813,58 +137,90 (+0,36%) Nasdaq
16.257,48 +101,15 (+0,63%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,72 +0,61 (+0,78%) Bitcoin EUR
59.427,74 +102,24 (+0,17%)
Novozymes A/S (NZM2.MU)
| Chiusura precedente | 52,30 |
| Aperto | 54,80 |
| Denaro | 54,30 x N/D |
| Lettera | 54,40 x N/D |
| Min-Max giorno | 54,80 - 54,80 |
| Intervallo di 52 settimane | 36,50 - 57,30 |
| Volume | |
| Media Volume | 60 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 03 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNovozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices. Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the lau
- GlobeNewswire
Novozymes and Bactolife join forces to significantly reduce post weaning diarrhea and antibiotic use among weaner pigs
The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption. Copenhagen, Denmark – 4 September 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising prod
- GlobeNewswire
Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook
After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3% organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing. COPENHAGEN, Denmark – August 9, 2023. Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the fi
